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Eberhard Ritz, Feature Editor
Renal Transplant-Associated Hyperuricemia and Gout
DAVID M. CLIVE
Division of Renal Medicine, Department of Medicine, University of Massachusetts Medical School,
Worcester, Massachusetts.
Gout is a common problem among renal transplant patients
with a prevalence of 2 to 13%. Hyperuricemia is even more
common (1–7). This association is important in two respects.
First, gout is a disabling disease, and may cloud the outcome of
a patient for whom rehabilitation has been particularly hard
fought. Second, the treatment of gout in renal allograft recip-
ients poses more potential pitfalls than in the general popula-
tion.
This article will explore the metabolic basis of gout in
allograft recipients. The currently available methods for treat-
ing gout will be examined with particular emphasis on drug
interactions and specific needs of the transplant patient.
Pathophysiology of Hyperuricemia and Gout
Gout is a painful disorder caused by an inflammatory reac-
tion to monosodium urate crystals in joint fluid and periartic-
ular tissue. The propensity for developing gout is directly
related to tissue uric acid content. Most uric acid in the extra-
cellular fluid is in the form of monosodium urate. A uric acid
concentration .7 mg/dl favors the spontaneous crystallization
of monosodium urate. The actual probability of gout arising in
a joint depends not only on the tissue content of urate, but the
pH and temperature of the joint fluid, as well as its macromo-
lecular constituency. However, any condition promoting in-
creased production or reduced excretion of uric acid can pre-
dispose to gout.
In primates, the kidneys are the main route for disposal of
purine metabolites. Uric acid is freely filtered by the glomer-
ulus. Tubular processing of uric acid is complex. Secretion
occurs in the early proximal tubule via an organic acid trans-
porter. At more distal sites in the proximal tubule, reabsorption
and further secretion occur. Other organic anions compete with
urate for proximal secretion; thus, uric acid levels may rise in
patients with lactic acidosis or ketoacidosis.
To the extent that the body’s uric acid content rises with
reduced excretion, one might surmise that gout is common
among patients with chronic renal failure (CRF). In fact, its
prevalence is lower than expected, an observation that may
have several explanations. Extrarenal disposal of uric acid is
probably enhanced in CRF (8). In addition, the fractional
excretion of uric acid rises in remnant nephrons (9–11). The
importance of this phenomenon is upheld by the observation
that tubulointerstitial renal diseases demonstrate an especially
strong tendency toward hyperuricemia (12). Finally, there is
evidence that the inflammatory response to monosodium urate
crystals may be suppressed by the uremic state (13,14).
Hypertensive nephropathy is associated with high serum uric
acid levels. It has been hypothesized that sodium-dependent
hypertension and hyperuricemia may be pathogenetically
linked, possibly reflecting damage to the peritubular microcir-
culation causing reduced delivery of uric acid to its tubular
secretion sites, or increased ambient generation of lactate to
compete for secretion at those sites (12).
Many drugs and toxins influence nephronal handling of uric
acid. Several of these deserve mention. Lead intoxication may
evoke a syndrome of hypertension, progressive renal insuffi-
ciency, and hyperuricemia. Both loop and thiazide diuretics
reduce uric acid excretion, presumably by causing mild volume
depletion with consequent enhancement of proximal tubular
reabsorption. Loop agents may also compete with uric acid for
secretion by the proximal organic acid transporter.
Uric Acid and the Renal Allograft
Several factors may contribute to the high prevalence of gout
among renal transplant recipients (Table 1). Renal allograft
recipients are prone to hypertension and edema, and diuretics
are commonly used in their management. Renal uric acid
excretion may be impaired simply on the basis of poor graft
function. When uric acid handling was examined in patients
with functioning kidney transplants in the precyclosporine era,
no consistent abnormalities in fractional reabsorption or excre-
tion of uric acid emerged. This argues against any specific
impairment in uric acid excretion inherent to transplantation
itself (15–18). In occasional patients, hypouricemia and hyper-
uricosuria were reported and were attributed to the uricosuric
effect of steroids (19) or to proximal tubular dysfunction (20).
It is clear that the risk of gout attributable to cyclosporine is
greater than that of any other factor in renal transplantation.
Cyclosporine’s adverse effects on renal excretion of uric acid
were recognized shortly after the drug came into widespread
clinical use. The mechanism by which these effects occur has
been the subject of considerable investigation, yielding a vari-
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ety of conclusions. Cohen and coworkers noted a reduction in uric
acid clearance among their cyclosporine-treated transplant pa-
tients. Pyrazinamide-inhibitable uric acid secretion was higher in
these patients than in non-cyclosporine-treated patients, suggest-
ing that cyclosporine may potentiate tubular uric acid secretion.
However, because fractional uric acid excretion was no different
from that of patients not receiving cyclosporine, these investiga-
tors concluded that the drug must simultaneously induce an off-
setting increase in uric acid reabsorption, and that the observed
reduction in uric acid clearance must be attributable to reduced
glomerular filtration (21). In a study by Hansen, the anti-urico-
suric effect of cyclosporine also appeared to be due to a reduction
in the filtered load (22).
The majority of studies have tended to implicate impaired
tubular handling of uric acid in the hyperuricemia of adult and
pediatric transplant patients receiving cyclosporine (10, 23–
27). Marce´n and colleagues reported that cyclosporine inhibits
probenecid-stimulated tubular secretion (23). In other studies
that used clearance techniques, however, uric acid reabsorption
was found to be augmented by cyclosporine (24,26). In a study
of renal transplant patients receiving cyclosporine, Zawadzki
and colleagues found that probenecid-stimulated uric acid se-
cretion was lower in patients with hyperuricemia than in nor-
mouricemic patients. These authors found that treatment for
8 d with nifedipine increased maximal stimulated uric acid
secretion by 45.7%.
This response, while substantial, was not sufficient to nor-
malize fractional uric acid excretion since the increment in
secretion was largely offset by a concomitant increase in post-
secretory reabsorption. In this study, it is not clear whether the
enhancing effect of nifedipine on tubular secretion of uric acid
derived from its ability to reverse cyclosporine-induced renal
vasoconstriction or from some other action upon uric acid
secretory transport (25). The pathogenesis of hyperuricemia in
patients who develop fixed arteriolopathic lesions from cyclo-
sporine may have some similarity to that of patients with
hypertensive nephropathy. The rarefaction of renal microvas-
culature in both settings could easily impair the delivery of uric
acid to its sites of secretion (12).
The impact that cyclosporin A has had in the pathogenesis of
gout and hyperuricemia among transplant patients is demon-
strated in Table 1, which displays prevalence data from several
studies. Most of these data represent observation periods of 5
yr or less. The incidence of gout among non-cyclosporine-
treated patients may be higher than reflected in the table. In a
recent report from the Cleveland Clinic of transplant patients
treated solely with azathioprine and prednisone and followed
for more than 20 yr, gout occurred in 23% (28). It is therefore
possible that in addition to predisposing patients to gout, cy-
closporine may accelerate its appearance.
It is unclear whether additional factors further amplify the
risk of hyperuricemia and gout in patients receiving cyclospor-
ine. Diuretics may heighten the risk of gout in patients on
cyclosporine (1,23,29,30), but their contribution to that risk has
been reported by some groups to be negligible or small (3,5,6).
Few investigators have examined the relationship between
cyclosporine levels and hyperuricemia or gout. West did not
find evidence of such an association (6). Lin found a weak, but
statistically significant, correlation between the trough cyclo-
sporine and serum uric acid levels (1). Renal insufficiency, as
defined by increased serum creatinine levels, has in most
studies correlated with hyperuricemia (1,2,23,30), although
serum creatinine levels may be a surrogate for cyclosporine
level. Renal allograft recipients may develop their first attack
of gout at any time from months to years after transplantation.
Because cyclosporine doses and levels diminish with time in
most immunosuppressive protocols, the logical inference is
that the risk of gout depends more on exposure to cyclosporine
per se than on its level or dose.
Hyperuricemia and gout have been reported among cardiac
allograft recipients treated with cyclosporine (31), as well as
among nontransplant patients receiving cyclosporine for auto-
immune disease (32). The related calcineurin-inhibiting immu-
nosuppressive agent tacrolimus has also been found to cause
hyperuricemia (33).
Clinical Characteristics of Gout in Renal
Allograft Recipients
Gout in renal transplant patients behaves similarly to gout in
other settings. As noted, the onset of the disease may occur
within months of transplantation or after a period of years; it is
invariably preceded by a period of hyperuricemia. The inflam-
matory manifestations of transplant-associated gouty arthritis
may be sufficiently pronounced to raise concern regarding the
possibility of septic arthritis (34). Patients may have monoar-
ticular or oligoarticular presentations with hot, tender joints.
Fever, chills, and leukocytosis are seen in particularly dramatic
attacks. The intensely inflammatory nature of gout is appre-
ciable in transplant patients as in the general population. Main-
tenance immunosuppression neither obviates nor mitigates
symptoms in all patients. Although it is possible that a patient’s
threshold for manifesting clinical gout may be influenced by
their immunosuppressive therapy, this remains to be proven.
Table 1. Prevalence of hyperuricemia and gout in renal
transplant patients
Source
CsA Non-CsA
1 Uric Acid Gout 1 Uric Acid Gout
Lin (1) 84 7 30 0
Ahn (2) 51 3.5 19 0
Delaney (3) 82 28 28 8
Gores (5) 80 4.6 55 0
West (6) NR 9.7 25 0
Kahan (7) 30 2 NR NR
Ben Hmida (4) NR 13 NR 0
a Figures in columns are all percentages. CsA,
immunosuppressive regimen based on cyclosporin A, generally in
combination with prednisone; Non-CsA, immunosuppressive
regimen not containing cyclosporin A, generally comprising
azathioprine and prednisone; NR, not reported.
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Gout in allograft recipients, as in other patients, has a pre-
dilection for the first metatarsophalangeal joint, as well as
wrists, knees, and elbows. There are some interesting qualita-
tive differences, however. Cohen has described proximal dis-
tributions of gouty arthritis involving hips, shoulders, and
sacroiliac joints (35). Cohen has also reported gouty enthesitis
in five of seven patients who subsequently developed arthrop-
athy (36). We have seen numerous patients in our transplant
center with extra-articular gout presenting as a tenosynovitis of
the dorsum of the foot and ankle.
Tophi may also be more common in the posttransplant
setting than elsewhere (Figure 1). Baethge and colleagues
reported four cases of tophaceous gout occurring within 5 years
or less of renal transplantation (37). Although no literature
exists regarding the specific prevalence of tophaceous disease
among transplanted patients with gout, we have seen them
frequently among our patients, and anecdotal information ex-
changed with other centers suggests that this experience is
fairly typical. In the 1970s, the prevalence of tophaceous gout
was reported to be declining in the general population, proba-
bly reflecting more effective uric acid-lowering therapy and
prophylactic management (38).
The apparent increase in incidence of tophi among transplant
recipients probably relates to cyclosporine’s potency in pro-
moting uric acid retention. Immunosuppressive therapy may
exert a permissive effect in this regard, delaying the manifes-
tation of overt symptoms, and recognition of the need for
treatment, until an extremely large uric acid burden has been
accrued. These hypotheses are not inconsistent with the rela-
tively later appearance of gout in renal transplant patients not
receiving cyclosporine (28).
The presence of tophi can simplify the diagnosis of gout and
help clarify the therapeutic approach; tophi pose a clear indi-
cation for uric acid-lowering therapy. In other respects, tophi
are problematic. They may be disfiguring. Tophi may also
compound the discomfort of gout by virtue of their bulk;
Peeters and Sennesael reported a patient with low back pain
due to spinal cord compression from a large tophus (39).
Subcutaneous tophi may erode through the overlying skin and
drain cutaneously. Such lesions can provide a nidus for serious
infection and sepsis (P. Kimmel, personal communication).
Therapy of Hyperuricemia and Gout in Renal
Transplant Recipients
Treatment of Gouty Arthritis
The approach to treating gout in this patient population
parallels that of most patients, albeit with a few precautions.
Anti-inflammatory therapy should be initiated as soon as the
diagnosis is made. There are several choices. Colchicine is
effective for most patients. The dose may be titrated until
gastrointestinal side effects occur. A typical starting dose is 0.6
mg every 6 h. At the appearance of diarrhea, abdominal cramp-
ing, or nausea, the dose may be reduced to 0.6 mg once or
twice a day and continued for the duration of symptoms.
The danger with colchicine resides in its ability to induce
myoneuropathy (40–47). A reversible disorder, it may never-
theless be highly disabling. It should be suspected in any
colchicine-treated patient developing weakness and an elevated
serum creatine kinase level. The diagnosis may be confirmed
by muscle biopsy, which reveals a characteristic vacuolated
myopathy. Impaired renal function clearly enhances the risk
for this complication, which may explain the number of reports
occurring in the setting of renal transplantation (40,41,44–47).
For this reason, the Cleveland Clinic group has recommended
the sparing approach to colchicine use in renal transplant
patients outlined in Table 2 (28). Some patients are unable to
tolerate even modest exposure to colchicine. One of our renal
allograft recipients developed biopsy-proven colchicine myop-
athy while being treated for gout. This patient improved after
cessation of colchicine therapy, but relapsed when challenged
with a dose as small as 0.6 mg/d.
Nonsteroidal anti-inflammatory drugs (NSAID) are an ef-
fective alternative to colchicine in treating gouty arthritis.
These agents can adversely affect renal hemodynamics in
susceptible individuals, and may also cause hyperkalemia
(48,49). Because these same effects occur in association with
cyclosporine, NSAID must be used extremely cautiously in
renal transplant patients, particularly those with compromised
graft function (50). One of the more “renal sparing NSAID”
such as sulindac or a nonacetylated salicylate may be admin-
istered, but these are not always effective against a full-blown,
established attack of gout. Clinicians using salicylates should
be aware of their odd dose-dependent effects on uric acid
Figure 1. Digital tophi in a patient with gout. Courtesy of Dr. David
F. Giansiracusa.
Table 2. Protocol for the use of colchicine in the treatment
of acute gout in renal transplant recipientsa
Day Dosage Regimen
1 Colchicine 0.6 mg/h 32 maximum; stop if
diarrhea occurs
2 Colchicine 0.6 mg/h 32 maximum; stop if
diarrhea occurs
3 to 10 Colchinine 0.6 mg/d; stop if diarrhea occurs
a Modified from reference 28, with permission.
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metabolism. At low doses, these agents inhibit urate excretion
and may raise plasma urate concentrations. Their effect on uric
acid handling is neutral at intermediate-range doses, but large
doses may actually be uricosuric (51).
If a more potent NSAID is administered, we recommend
monitoring blood chemistry and renal function at least weekly
for the duration of therapy. Although their specific risks have
not been fully studied, the new cyclooxygenase-2 inhibitors,
such as celecoxib, may be less likely to induce deleterious
renal side effects than conventional NSAID (52,53). In the
future, these agents may prove a safe means for treating gout in
transplant patients. They are presently approved only for use in
rheumatoid arthritis and osteoarthritis and, for now, their ex-
pense is unlikely to be borne by insurers for use in gout.
Corticosteroids constitute yet another therapeutic choice for
the management of an acute gouty attack. Most transplant
patients are already on small, maintenance regimens of pred-
nisone or methylprednisolone. An acute gouty episode may be
treated by increasing the steroid regimen to the equivalent of
0.5 to 1.0 mg/kg per d of prednisone given for 3 to 7 d and then
tapered to the maintenance steroid dose within a 14-d period.
Adrenocorticotrophic hormone (ACTH), 40 to 80 IU given
intramuscularly, is a reasonable alternative to a course of
prednisone for patients on low maintenance steroid doses. The
injection may be repeated if necessary. Unfortunately, ACTH
is subject to variations in availability.
Antihyperuricemic Therapy and Prophylaxis
against Gout
Daily small doses of colchicine, generally 0.5 or 0.6 mg/d,
are often effective in prophylaxing against recurrent gouty
attacks. The use of this agent, even in small doses, is to be
avoided in patients with a previous history of colchicine-
induced myoneuropathy.
Antihyperuricemic therapy represents another approach to
preventing gout. In a typical patient population, this may be
accomplished in either of two ways: increasing uric acid ex-
cretion through the use of uricosuric agents, or attenuating the
production of uric acid with allopurinol. The drug reduces the
metabolism of purines to uric acid by inhibiting the activity of
the enzyme xanthine oxidase. This action of allopurinol also
enables it to retard the breakdown of the purine antimetabolite
azathioprine, which remains in widespread use among trans-
plant patients for antirejection chemoprophylaxis. Extreme
care should therefore be exercised when introducing allopuri-
nol to the regimen of a patient receiving azathioprine (52). If
excessive myelosuppression is to be avoided, the azathioprine
dose should be lowered to 25 to 50% of the usual amount, and
blood cell counts should be followed closely. Renal insuffi-
ciency predisposes to severe allopurinol toxicity, by permitting
retention of the metabolite oxipurinol (54,55). Therefore, the
starting dose of allopurinol should also be reduced in the
transplant setting (100 to 200 mg/d) (28). Mycophenolate
mofetil has replaced azathioprine for chemoprophylaxis of
rejection in many protocols. The pharmacologic benefit of this
agent also resides in its ability to alter purine metabolism. It is
much more selective in this regard than allopurinol, inhibiting
only the de novo path of purine synthesis. For this reason, plus
the absence of an effect of allopurinol on mycophenolate
metabolism, these two drugs are easier to use safely in com-
bination than are allopurinol and azathioprine (56).
Allopurinol is generally more effective than uricosuric ther-
apy because its antihyperuricemic effect is independent of
renal function. Patients allergic to allopurinol, or in whom the
drug has proven difficult to use safely, may be given uricosuric
agents, recognizing that such agents may fail to promote the
desired uricosuric response. Uricosurics are unlikely to be
effective in patients with significant graft dysfunction, i.e.,
creatinine clearance ,30 ml/min. Furthermore, as already
noted, probenecid may be ineffective in stimulating uric acid
secretion in the presence of cyclosporine. Occasionally, the
opposite condition may prove true. In rare cyclosporine-treated
transplant patients, excessive uric acid excretion has been
reported to cause uric acid lithiasis (57–59) and even acute uric
acid nephropathy (60). Uric acid excretion should be measured
periodically in transplant patients receiving drugs such as pro-
benecid, and they should be monitored sonographically at
regular intervals for urinary calculi. In hyperuricosuric patients
(24-h uric acid excretion .750 mg) or those with a history of
uric acid calculi, a prudently high fluid intake should be
recommended, and consideration should be given to alkalin-
ization of the urine with acetazolamide or sodium bicarbonate.
Cyclosporine withdrawal may be considered for transplant
patients with recurrent, severe gout that cannot be managed
safely or effectively through any of the above means. Hyper-
uricemia due to cyclosporine generally reverses upon discon-
tinuation of the drug (61–65). The risks and utility of this
maneuver obviously warrant careful consideration by both
patient and transplant clinician. Substitution of tacrolimus
would probably offer no advantage, because it, too, can cause
hyperuricemia (33).
Conclusion
Hyperuricemia and gout are common problems among renal
transplant recipients. Their prevalence is clearly attributable to
cyclosporine use, although individual patients may have other
risk factors as well. Cyclosporine lowers urinary clearance of
uric acid; the specific mechanism for this is unknown, but may
involve alterations in tubular transport. The therapy, both pre-
ventive and remedial, of gout may be particularly challenging
in these patients. Barring specific contraindications, patients
with an established history of hyperuricemia or gout at the time
of transplantation should probably be on uric acid-lowering
therapy at the same time cyclosporine treatment is initiated.
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